Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How would it be Humanigen’s revenue stream? It belongs to Durrant and Taran, there may be some measly payouts down the road that could make this worth a couple of cents but it would still have to regain currency for that to matter.
If Lenz was going to be HGEN’s revenue stream why spend 2 million dollars to take it to Tarant? Sorry Jay that doesn’t make sense to me.
Well, first of all, I don't see a revenue stream for Taran. It will be Humanigen's revenue. And did you see Durrant resign as Humanigen's CEO? I didn't.
The in-process structural change has not diminished Humanigen's capacity to execute their business plan. I'm not worried at all. In act, I'm excited to see how all the pieces will fit together.
The bankruptcy judge did not share your pessimistic view.
I wish i felt the same. I’ve seen no evidence or reason to think Taran is going to magically share revenue with former LENZ owner Humanigen. Crushing blow to folks holding bankrupt stock from HGEN. Cameron appears to have moved on completely. What is giving you hope or feeling that HGEN stock has future value?
It's a very exciting time for us, Jim!
Following an amazing eight-year, hugely intense journey at Humanigen, recently closed on acquiring the Humanigen assets and placing them in Taran, a Delaware C-corporation, with UK and Australian wholly-owned subsidiaries.
Taran is focused on helping bring life-saving medicines to patients, including lenzilumab ("LENZ") and ifabtotuzumab ("IFAB") in various leukemias, Graft vs. Host Disease and cancer, with possibilities in multiple other areas of high unmet medical need.
In regards to my oft-wondered-about covid pneumonia reinfection rate in lenz-treated patients, which I think could be an absolute game-changer for Humanigen's lenzilumab, I learned last night that I may again have to re-phrase my question, and likely have to ask more than just one question. But just to get started, let me ask the following.
In patients diagnosed with covid pneumonia, and treated with lenzilumab, what is the recurrence rate of those patients presenting with SARS-CoV-2 nucleocapsid proteins after treatment? (I'll have to pin this post to remember how to ask that question).
As my question was originally phrased, I didn't know better than to exclude subsequent presentations of covid found in spike proteins. The studies I reviewed last night demonstrate that covid in the spike proteins has no relation to how well lenz prevents future infections. Rather, as I read the studies I will link, covid found in spike proteins is mRNA vaccine-induced. So lenz-treated patients who subsequently present with covid spike proteins, have no bearing on the efficacy of lenz.
Attached is an autopsy report of a 76 year old man, which was used as a case study. The patient had no history of covid, but the pathologist found covid spike proteins leading to the heart and brain. It's a fascinating study which, along with a different, un-related discussion concerning San Vincente in the Darian Pass, kept me up all night reviewing.
The presentation gets off to what might be perceived as a slow start, but don't fast forward past the 11 minute mark, of the 28 minute video.
AND THE FDA AND NIH BEAT GOES ON: Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move https://www.cnbc.com/2024/03/08/eli-lilly-alzheimers-drug-fda-approval-delayed.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Interesting niche. But I don't see anything about production turnaround, and it appears that their CAR-T is designed to enhance mitigation of CCR-9. I think Gracell's 24 hour turnaround for CAR-T is a much better, even revolutionary, alternative, which I hope that lenz is a part of making that happen.
I see that they also provide CRISPR services. I think that lenz was developed with that gene-editing technology. But even so, I'm not comfortable with it, generally. And I see that GenScript also provides mRNA solutions, and I am becoming increasingly wary of that.
Lots and lots of potential with those technologies, but way too much opportunity for abuse of those capabilities.
https://www.genscript.com/?src=google&utm_source=google&utm_medium=cpc&utm_campaign=GenScript-ECPC_NA&jiraid=12194&gad_source=1&gclid=EAIaIQobChMIzsnPnL_ihAMVGy7UAR2UUQsxEAAYASAAEgJy3vD_BwE
Do you have a minute? Do you have 51 minutes?
I had never heard of Sharyl Attkisson, or her "Full Measure" weekly broadcast program, but I was fortunate enough to have just finished watching her program on "The Covid Clots," and I highly recommend that you watch it. It so happens that I am scheduled for an exam by my vascular surgeon on Friday, because it has been a year since he did the angioplasty/atherectomy on my leg artery. And I'm curious to see if he is familiar with the information I just learned about covid clots.
You brought this issue up last month, Jim
February 14, 2024
Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173844576
and I gave you my thoughts on this subject at that time
02/14/24
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
https://investorshub.advfn.com/boards/replies.aspx?msg=173844576
What right does Taran have to recall the loaned shares? Did they loan any of those shares? What clinical trial relationships does Taran have with Humanigen's partners, working on bringing lenz to market for CMML, or aGvHD, or Covid, or for any of Sanofi's oncology or asthma indications? Taran's CEO Durrant could make Humanigen's CEO Durrant sign a licensing agreement, which he may have done already, if that would alleviate your concern.
But, Taran did not buy Humanigen. I think Humanigen remains on track with all of their on-going work, and the pending results of all that work are what shareholders have to look forward to accomplishing. If you think I'm missing something, maybe I am, in which case please inform me of what that is.
Doesn’t Taran own Lenz now? What value is there and assets in bankrupt Humanigen?
Is the Sanofi spin-off of their healthcare division designed to partner with Humanigen on the asthma market, and more?
According to Humanigen's Featured Presentation, "...historical clinical results could provide basis for global partnering discussions."
asthma mentioned on five slides in the chart deck
https://ir.humanigen.com/English/events-and-presentations/default.aspx
Does Sanofi think that lenz could do better than their Regeneron partner, using Dupixent? Or is Sanofi looking to expand their supply chain?
https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-fda-approved-first-and-only-treatment
There are worse problems to have than trying to figure out what will be the most valuable entity for Humanigen shareholders 🙂. You make some good points and I can understand your enthusiasm, which I share, for our success in Australia.
But, if the loaned shares are recalled, chances are it will be with news, and Humanigen's value could skyrocket well beyond the value of their subsidiaries or Taran, if that news is related to covid prevention/treatment authorization. And in that regard, I now see news from the UK Ministers accusing the Health Secretary, "...of withholding data that could link the Covid vaccine to excess deaths, and criticised a “wall of silence” on the topic.
A cross-party group has written to Victoria Atkins to sound alarm about the “growing public and professional concerns” at the UK’s rates of excess deaths since 2020."
https://www.yahoo.com/news/health-secretary-urged-release-data-181513423.html
I'm disappointed that the UK regulators did not act independently and much earlier to approve lenz for covid. So I'm glad to see pressure building on them in this regard. I think a study of lenz patients could actually show "decreased deaths" and negligible (or at least show a statistically significant lower level) of covid pneumonia reinfections.
I see the value in subsidiaries(specifically, the Australian one )as more immediate and substantive compared to the IP with Taran . As it is only holdi ( IP and inventory). The only potential revenue for Taran will be licensing fees from future sales from the subsidiaries of Humanigen .. This structure essentially separates the IP company from the operating. Entities . This was also necessary for providing the DIP financing . Taran does not have access to the rights that the Australian company has and data on clinical trials for a potential biologic submission as it was excluded from the sale to Taran .
You can never be sure how a bankruptcy court judge is going to rule, even with guys like Barliant (?) helping the company through the process. I appeared once in a corporate bankruptcy case, where the issue concerned naked shorting. The company was being naked shorted tens of millions of shares everyday, even though they were on the Failure-to-Deliver (FTD) list. The judge told me that he thought I (shareholders) had a case. But he couldn't see how naked shorting negatively impacted the issuer. I was dumb-founded, and I mean literally.
So, I can see how transferring intellectual property rights to Taran could have been a safeguard, pending how the judge ruled.
Beyond that, in my opinion, it has made a lot of sense to use Dale's entities as we have, broadly, as what I call our financing arm. I hope, going forward, that we continue to segregate our financing and operational activities, in the manner that we have. But I have to think that the value of Humanigen's shares is a reflection of the value of our intellectual property, and I expect that issue will be addressed as you mentioned, either by way of exclusive licensing, or with a potential merger through subsidiaries of Humanigen and Taran.
"COVID-19 remains a danger, especially to older people and those with underlying medical conditions. There are still more than 20,000 hospitalizations and more than 2,000 deaths each week due to the coronavirus, according to the CDC. And people 65 and older have the highest hospitalization and death rates."
https://www.yahoo.com/news/older-us-adults-another-covid-191550624.html
No, thanks. I'll have lenz, please.
You're right, eb.
And there's so much going on. Today, for example, Baudax filed a CH11. Will this give us the opportunity to bid on Tera-Immune?
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1780097/000119312524049000/d800225d8k.htm
And Sanofi's notice of appointing 3 Independent Directors yesterday, having already announced plans to spin-off their healthcare business, suggests preparations to ready the spin-off for Nasdaq listing.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412dex993.htm
And as Preciouslife1's article informed us today, "Novavax expects full-year 2024 revenue to come in between $800 million and $1 billion. That forecast reflects an expected $500 million to $600 million in revenue from advanced purchase agreements and $300 million to $400 million from commercial market product sales, royalties and other revenue from the company’s “partner-related activity.”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173936647
"What will be left in Humanigen ?"
If our float is as once reported, 229M shares, I believe that 110M (~90% of our OS) of those shares could be owned by Humanigen. That might be a whole lot of nothing, at a share price of $0.0001, or so, and no regulatory authorizations or approvals for lenz, and no customer demand.
But that could change instantly with news.
Pick a share price, if the brokerages are forced to buy-in shares, whether from a recall of the loaned shares, or a merger, and remember...the company owns most of the shares. So I'm hoping to sell some shares for about $200, especially if we're still on the Expert Market.
But, THERE'S SO MUCH POTENTIAL, that even if I can't sell at my target price, just our fundamental price could be in the $60 range ($8B, for example.) market cap, if we can get into the covid prevention market with the Novavax vaccine, and/or regulatory approval for CMML, not to mention a PRV, Humanigen could end up with a boat load of cash.
Jay, I see this being the way to "call in" all the loaned and counterfeited shares....one brilliant way.
Sorry I forgot the only thing excluded from APA is the foreign subsidiary. I hope that’s enough in value for a favorable merger with Taran on terms favorable for humanigen shareholders .
Jay . Thanks for the reply . The document you posted shows the APA is for substantially all assets ( including inventory and IP) and also assumes most contracts to Taran . What will be left in Humanigen ? . I am assuming you believe there will be another potential merger between Taran and humanigen which will cover/ protect the shareholders of humanigen . I am hoping that’s the case . But why would Taran do it ?
Hello, InfinitePhoenix4. Welcome to the room, and thank you for posting your first Ihub message here. I appreciate the thought you put into it.
I think it is very likely that lenz could receive it's first regulatory approval in Australia, to treat CMML. It's also possible that a Priority Review Voucher in the range of ~$100M could be awarded with that approval.
But Taran didn't buy Humanigen. Taran bought the intellectual property rights. Do you agree, because I don't think you do? Let's start there, if you want.
https://document.epiq11.com/document/getdocumentsbydocket/?docketId=1061258&projectCode=HUM&docketNumber=155&source=DM
I haven't given the document the full study it deserves, because I have total confidence in management. I am as confident in Dale's stewardship of Humanigen's shares, as I am in Durrant's purchase of the intellectual property rights. Besides, I think we will see a merger, anyway. So I don't foresee value being left behind, once the share structure and the intellectual property rights are rejoined (joined), by some means.
I hope this all becomes moot, but even more so, I also hope to see the recall of the loaned shares, in short order. But I do agree that our value lies in the intellectual property, and have said that, "To be honest, I think it would take a lot more study for me to feel that I have confidence in making a deduction about HOW these guys have navigated during this bankruptcy." I'm looking forward to the completion of our restructuring.
Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs https://www.cnbc.com/2024/02/28/novavax-nvax-earnings-report-q4-2023.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard
Jay. I have been following your posts . Can you comment on my understanding below . The Australian subsidiary pays license fee to humanigen for lenz. It’s owned by humanigen which was excluded from the sale to Taran . Taran owns the license now for lenz. The clinical trial is being conducted by the subsidiary in Australia. The Australian subsidiary may receive the approval for lenz if it gets through the trial . That’s the value that’s been left behind . Taran would continue to receive the license fees for any potential sales by the Australian subsidiary post approval . Humanigen’s value now is in the subsidiary.
We're not at our destination.
LOL Sorry Jay I don't understand all of the legal jargon and I am really not sure what is going on with this bankruptcy.
From what I am reading it looks scary to me.
Either way I am just going to hold and wait and see and I am not going anywhere. :)
I don't understand you guys. The bankruptcy was brilliantly designed and executed, and the CH11 was successfully achieved. Between the rights Humanigen retained by way of the Excluded Assets, and also having a foreign subsidiary unencumbered to maneuver, I don't know what we can't do, that needs to be done, as the restructuring is completed.
I agree the court filings are pretty ugly for now, but I guess we will just have to wait and see what happens after the bankruptcy gets discharged.
Yeah it’s definitely strange since no one stateside can buy shares and it sounds like someone from over seas who can buy shares is spreading some discontent.
That’s a hopeful sign that something could be up, but from reading the court filings and seeing the bankruptcy proceedings… it just doesn’t look good.
Hope Jays right of course, I’m not selling my shares, I have plenty of capitol gains losses to ride this out for a longtime!
The fact that all of these new accounts are showing up here telling us how we are all toast really is interesting? This actually gives me some hope that something may be up behind the scenes? I know one thing for sure and that is I am holding my 4.1 million shares very tightly here. I would love to see Jay be right about some of this.
You are right in that it may take some time, but If they bring it current we could be looking at a nice run here even if it only is a shell.
Yep, may take a while, who knows, but I think it’s toast for any recovery. Here’s to wishing haha!
This is my first bankruptcy gamble with the new EM exchange…it sure wasn’t as fun as other bankruptcy plays I’ve traded before that existed!
At this point it appears that is the case, but there maybe value in the shell as all of the debt will get discharged with the completion of the bankruptcy. We maybe looking at a few cents value for our shares if they bring this back off of the grey-sheets.
Company of interest Sanofi, who appears to have long ago converted their common shares of Kalobios into preferred shares, today released a 6-K regarding several of their mabs and clinical trials. Also included was a press release concerning the appointment of three new Independent Directors. I wonder if the new Independent Directors are being appointed to gain Nasdaq compliance in the US, ahead of the spin-off of their healthcare division.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412d6k.htm
VIKING Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Viking said its Phase 2 Venture trial showed weight loss in patients receiving the VK2735 treatment.
I don’t know man, but to me it looks like Durrant took Lenz and left us with debt and a shell…Jay keeps talking about a share recall, I don’t see it, a share recall if possible would have happened before they decide to sell the assets.
IMO it would have made sense to do that before Ch11, cause the squeeze and bring value to the shares and raise capitol for the company. That idn’t happen….
We may get lucky with a bone tossed to common shares, but a squeeze and a share recall doesn’t sound like it would make sense at this point.
I think Durrant gave up trying to run HGEN. He has taken his work somewhere else and left us holding our bags.
Can somebody please update me where we stand with our shareholder positions? Are we dissolving/invalidating our shares such as transferring the ip to Taran or is Humanigen still going to remain active and viable? I stepped away from the board for a few because new accounts are appearing and seem to be spamming the board.
With Gracell having completed becoming a subsidiary of AstraZeneca, and deregistering their stock on Nasdaq, I'm going to replace them with Sanofi (SNY) as one of the stocks I watch for SEC filings.
Sanofi is showing several recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001121404&owner=exclude
I don't think you're giving full consideration to both Humanigen's and Taran's blank-slate foreign subsidiaries, and to how they may be used to capitalize on the use of the Excluded Assets recognized by the bankruptcy court judge. And that is totally understandable, and intended. I think that same lack of understanding is shared by certain of the unsecured creditors, who should appreciate management's ongoing effort which is, in part, on their behalf, in my opinion.
I don't see any real change, or impediments, to the accomplishment of management's goals. In fact, I see just the opposite, as management is free to proceed without the degree of financial constraints they have been under.
Humanigen management ran the company into the ground, didn't need to file bankruptcy except that prior management got the company for a credit bid, and netted that out with the Australian receivable.
Terrible managers of the business but brilliant in bankruptcy proceedings. Give the BOD props for that one.
Did we ever get played.
Great summaries of the filings, Biowa.
I will do that on the 2nd Million! :))
come on, at least make it for $2 or $3!
Any shorts who are desperate to cover I am giving you a Gift as I have 1 million shares up for sale at .40 cents per share.
The rest I will hold for much higher gains.
The judge in this case handles 10 cases per year. you think he has the time or resources to do full 'investigation' bankruptcy filing is procedure and lots of precedent cases.. no need to appeal. case closed.
there is less than 20 shareholders one shareholder owns 90% of the shares and is the controlling shareholder. I'm helping myself with this analysis of the situation and case. obviously the courts dont have the time or resources for such deep analysis of the chapter 11. With secure loans the creditors own the assets and equity and there is no auction. liquidating assets is chapter 7 when all assets are liquidated and any money left to repay any creditor. in this case there is no money or cash to pay any of the UNSECURED creditor 'fake claims' or unreasonable disputed claims, the defendent or debtor nor the court has the time to hear or prove whether those UNSECURED DISPUTED 'claims' or valid..in chapter 11 all creditor claims are DISCHARGED.
Well, another newly created account for the purpose of helping us poor HGEN holders. How nice you are. Oh, now I realize you are a trumper/magat.
The Judge could have just said , get out of my court and stop wasting the court time and cased closed to the creditor committee and debtor filing the chapter 11
you have fools who think they can sue if they lose in sport bet.
Followers
|
326
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
43428
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |